You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
和黃醫藥(00013.HK)將於2022年ESMO年會公佈呋喹替尼(Fruquintinib)治療難治性的轉移性結直腸癌的FRESCO-2國際多中心III期研究數據總結
格隆匯 09-08 06:35

格隆匯9月8日丨和黃醫藥(00013.HK)今天宣佈呋喹替尼的國際多中心臨牀試驗的結果總結,該研究共納入691名患者。上述數據已於即將在2022年9月12日舉行的2022年歐洲腫瘤內科學會(“ESMO”)年會上公佈的摘要中分享。該會議將在法國巴黎的巴黎凡爾賽門展覽館舉行。

美國德克薩斯大學MD安德森癌症中心胃腸道腫瘤內科副教授Arvind Dasari博士將於2022年ESMO年會上報吿FRESCO-2的研究結果。Arvind Dasari博士表示:“此項研究結果解決了難治性的轉移性結直腸癌領域巨大未被滿足的需求,無論對於患者還是醫學工作者來説,都令人感到十分振奮和鼓舞。呋喹替尼提供了一種潛在的治療新選擇,帶來更高的存活率及可控的毒性特徵。這些結果也為呋喹替尼進一步開發用於其他適應症及聯合療法創造了機會。”

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account